Evidence map›Paper›PMID 41203831›Full record

ArticleScientific reports2025

Metabolites associated with abnormal glucose metabolism responding to primary care lifestyle intervention.

Ville M Koistinen, Suvi Manninen, Marjo Tuomainen, Kirsikka Aittola, Elina Järvelä-Reijonen, Tanja Tilles-Tirkkonen, Reija Männikkö, Niina Lintu, Leila Karhunen, Marjukka Kolehmainen and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Ville M KoistinenInstitute of Public Health and Clinical Nutrition, University of Eastern Finland, Kuopio Campus, Kuopio, Finland.
Suvi ManninenInstitute of Public Health and Clinical Nutrition, University of Eastern Finland, Kuopio Campus, Kuopio, Finland.
Marjo TuomainenInstitute of Public Health and Clinical Nutrition, University of Eastern Finland, Kuopio Campus, Kuopio, Finland.
Kirsikka AittolaInstitute of Public Health and Clinical Nutrition, University of Eastern Finland, Kuopio Campus, Kuopio, Finland.
Elina Järvelä-ReijonenInstitute of Public Health and Clinical Nutrition, University of Eastern Finland, Kuopio Campus, Kuopio, Finland.
Tanja Tilles-TirkkonenInstitute of Public Health and Clinical Nutrition, University of Eastern Finland, Kuopio Campus, Kuopio, Finland.
Reija MännikköInstitute of Public Health and Clinical Nutrition, University of Eastern Finland, Kuopio Campus, Kuopio, Finland.
Niina LintuInstitute of Biomedicine, University of Eastern Finland, Kuopio Campus, Kuopio, Finland.
Leila KarhunenInstitute of Public Health and Clinical Nutrition, University of Eastern Finland, Kuopio Campus, Kuopio, Finland.
Marjukka KolehmainenInstitute of Public Health and Clinical Nutrition, University of Eastern Finland, Kuopio Campus, Kuopio, Finland.
Santtu MikkonenDepartment of Environmental and Biological Sciences, University of Eastern Finland, Kuopio Campus, Kuopio, Finland.
Marko LehtonenSchool of Pharmacy, University of Eastern Finland, Kuopio Campus, Kuopio, Finland.
Janne MartikainenSchool of Pharmacy, University of Eastern Finland, Kuopio Campus, Kuopio, Finland.
Kaisa PoutanenVTT Technical Research Centre of Finland Ltd, Espoo, Finland.
Ursula SchwabInstitute of Public Health and Clinical Nutrition, University of Eastern Finland, Kuopio Campus, Kuopio, Finland.
Pilvikki AbsetzInstitute of Public Health and Clinical Nutrition, University of Eastern Finland, Kuopio Campus, Kuopio, Finland.
Jaana LindströmInstitute of Public Health and Clinical Nutrition, University of Eastern Finland, Kuopio Campus, Kuopio, Finland.
Timo A LakkaInstitute of Biomedicine, University of Eastern Finland, Kuopio Campus, Kuopio, Finland.
Kati Hanhineva *Institute of Public Health and Clinical Nutrition, University of Eastern Finland, Kuopio Campus, Kuopio, Finland.
Jussi Pihlajamäki *Institute of Public Health and Clinical Nutrition, University of Eastern Finland, Kuopio Campus, Kuopio, Finland. jussi.pihlajamaki@uef.fi.

Funding

Lantmännens Forskningsstiftelse 2021H024Novo Nordisk Fonden 33980 and 63753Research Council of Finland 303537, 303643, 303644, 303645, T2D-Data project, 332465, 332464, 332466Research Council of Finland 321716Research Council of Finland 325022 and 352968
6 · The paper itself

Abstract

Type 2 diabetes can be prevented by lifestyle intervention. We aimed to identify metabolites that associate with glucose metabolism and respond to lifestyle intervention with evidence-based targets for nutrition and physical activity in individuals at high risk of type 2 diabetes. Standard oral glucose tolerance test (OGTT) was used to categorize 624 participants into those having normal glucose tolerance (NGT), isolated impaired glucose tolerance (IGT), IGT with increased fasting glucose (IGT + IFG), and type 2 diabetes. Plasma LC-MS metabolomics was performed to reveal metabolic signatures. The baseline group differences were analysed with the Kruskal-Wallis test and the effect of intervention with a linear mixed-effects model. Significant differences in the metabolite signature were observed between the baseline groups, particularly in amino acids, acylcarnitines, and phospholipids. Fatty acid amides, phospholipids, amino acids, dimethylguanidinovaleric acid, and 5-aminovaleric acid betaine responded most to the lifestyle intervention. Lysophosphatidylcholines containing odd-chain fatty acids showed associations with improved glucose metabolism. Twenty-five metabolites differed between the baseline groups, responded to the intervention, and were associated with changes in glucose metabolism. The findings suggest a metabolite panel could be used in distinguishing individuals with varying degrees of glucose metabolism and in predicting response to lifestyle interventions.

Indexed as

Blood GlucoseDiabetes Mellitus, Type 2GlucoseGlucose IntoleranceLife StyleAdultAgedExerciseFemaleGlucose Tolerance TestHumansMaleMetabolomeMetabolomicsMiddle AgedPhospholipidsBlood GlucoseGlucosePhospholipidsAcylcarnitinesAmino acidsFatty acid amidesImpaired glucose metabolismMetabolomicsPersonalized treatmentPhospholipids

Identifiers

PMID41203831
PMCPMC12594967

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.